Home - AME Clinical Trials Review

Join us at the 9th World Congress of Pediatric Cardiology & Cardiac Surgery

This year AME Clinical Trials Review (ACTR) as well as its sister journals and books published by AME Publishing Company will be on display during this exciting academic event! We would like to seize this great opportunity to meet our authors, editorial board members and readers. You are cordially invited to visit us at Booth 31.

AME and Wolters Kluwer aim to expand access to global medical research through new collaboration

The agreement broadens the reach of nearly 50 Open Access titles, contributing globally to over 5,000 articles

October 2, 2025 — Wolters Kluwer Health announced a new collaboration with AME Publishing Company, an Open Access publisher specializing in medical journals and books, headquartered in Hong Kong, China.

Reviewer of the Month (2025)

In 2025, ACTR reviewers continue to make outstanding contributions to the peer review process. They demonstrated professional effort and enthusiasm in their reviews and provided comments that genuinely help the authors to enhance their work.

Hereby, we would like to highlight some of our outstanding reviewers, with a brief interview of their thoughts and insights as a reviewer. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

Interviews with Outstanding Authors (2025)

In 2025, many authors shared their insights on clinical trials in our journal. Their articles published with us have received very well feedback in the field and stimulate a lot of discussions and new insights among the peers.

Hereby, we would like to highlight some of our outstanding authors who have been making immense efforts in their research fields, with a brief interview of their unique perspectives and insightful views as authors.

Is it time to recommend dual antiplatelet therapy for all following coronary artery bypass graft surgery?—an updated review of clinical trials

Rushmi Purmessur, Zeba Ahmed, Jason Ali
Review Article｜25 June 2025
doi: 10.21037/actr-24-180

The role of lisocabtagene maraleucel for relapsed/refractory follicular lymphoma: a commentary

Abigail T. Huetteman, Julio C. Chavez
Editorial Commentary｜February 25, 2026
doi: 10.21037/actr-25-18

Encorafenib, cetuximab and chemotherapy: a mole against BRAF mutant metastatic colorectal cancer

Benoist Chibaudel
Editorial Commentary｜February 25, 2026
doi: 10.21037/actr-25-80

From the PACIFIC to the ADRIATIC: a literature review of 38 years of failed maintenance trials in small cell lung cancer post-chemoradiation

Alexandria Lee, Misako Nagasaka, Sai-Hong Ignatius Ou, Zhaohui Liao Arter
Review Article｜February 25, 2026
doi: 10.21037/actr-25-71

First-line treatment strategies and potential prognostic factors in patients with KRAS G12C-mutant non-small cell lung cancer

Malak Alharbi, Nour Nassour, Vaishali Deenadayalan, Grace K. Dy
Review Article｜February 25, 2026
doi: 10.21037/actr-25-63

The role of minimal residual disease measurement in multiple myeloma

Bhavesh Mohan Lal, Nikhil Vojjala, Nikhila Sampath Kumar, Carolina Schinke
Review Article｜February 25, 2026
doi: 10.21037/actr-25-66

Clinical advancements in total neoadjuvant therapy for locally advanced rectal cancer: a narrative review

Angelo Pirozzi, Celine Hoyek, Naohiro Okano, Leticia Assad Maia Sandoval, Binbin Zheng-Lin, Oluseyi Abidoye, Cody Eslinger, Mohamad Bassam Sonbol, Mitesh J. Borad, Tanios S. Bekaii-Saab
Review Article｜February 25, 2026
doi: 10.21037/actr-25-58

Recent updates in targeted therapy for advanced non-small cell lung cancer with actionable genomic alterations: a narrative review

Fangdi Sun, Joel W. Neal
Review Article｜October 25, 2025
doi: 10.21037/actr-25-37

‹ ›

Cover image "A Picture in a Picture" by Dr. Anthony P Yim, MD More >>

Articles in Press

Past Issues

About actr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

General editorial enquiries:
Email: actr@amegroups.com
Copyright related contact:
Email: permissions@amegroups.com
Commercial Sales contact (Reprints, advertising, etc.):
Email: sales@amegroups.com

Letter to the Editor

Reply to: Xaluritamig: a first step towards a new target, new mechanism for metastatic prostate cancer

Kevin K. Zarrabi, Wm. Kevin Kelly

AME Clinical Trials Review

2026;

(25 February 2026)

PDF Full Text (942) COI Form Open Access

Editorial Commentary

Chimeric antigen receptor T cell therapy in prostate cancer: racing to prime time

Margaux E. Wooster, Mark N. Stein

AME Clinical Trials Review

2026;

(25 February 2026)

PDF Full Text (899) Peer Review File COI Form Open Access

Editorial Commentary

Long-term clopidogrel for secondary prevention—towards resolution of complex problem?

Akshyaya Pradhan, Monika Bhandari

AME Clinical Trials Review

2026;

(25 February 2026)

PDF Full Text (571) Peer Review File COI Form Open Access

Editorial Commentary

Encorafenib, cetuximab and chemotherapy: a mole against BRAF mutant metastatic colorectal cancer

Benoist Chibaudel

AME Clinical Trials Review

2026;

(25 February 2026)

PDF Full Text (405) Peer Review File COI Form Open Access

Editorial Commentary

Ibrutinib’s role in early-stage chronic lymphocytic leukemia: delayed progression but no survival advantage

Kelly Meza, Jacqueline C. Barrientos

AME Clinical Trials Review

2026;

(25 February 2026)

PDF Full Text (621) Peer Review File COI Form Open Access

Editorial Commentary

Asciminib: a revolution in the tyrosine kinase inhibitors era

Mario Annunziata, Fabio Stagno

AME Clinical Trials Review

2026;

(25 February 2026)

PDF Full Text (405) Peer Review File COI Form Open Access

Editorial Commentary

The role of lisocabtagene maraleucel for relapsed/refractory follicular lymphoma: a commentary

Abigail T. Huetteman, Julio C. Chavez

AME Clinical Trials Review

2026;

(25 February 2026)

PDF Full Text (1866) Peer Review File COI Form Open Access

Review Article

From the PACIFIC to the ADRIATIC: a literature review of 38 years of failed maintenance trials in small cell lung cancer post-chemoradiation

Alexandria Lee, Misako Nagasaka, Sai-Hong Ignatius Ou, Zhaohui Liao Arter

AME Clinical Trials Review

2026;

(25 February 2026)

PDF Full Text (508) Reporting Checklist Peer Review File COI Form Open Access

Review Article

Clinical advancements in total neoadjuvant therapy for locally advanced rectal cancer: a narrative review

Angelo Pirozzi, Celine Hoyek, Naohiro Okano, Leticia Assad Maia Sandoval, Binbin Zheng-Lin, Oluseyi Abidoye, Cody Eslinger, Mohamad Bassam Sonbol, Mitesh J. Borad, Tanios S. Bekaii-Saab

AME Clinical Trials Review

2026;

(25 February 2026)

PDF Full Text (1251) Reporting Checklist Peer Review File COI Form Open Access

Review Article

The role of minimal residual disease measurement in multiple myeloma

Bhavesh Mohan Lal, Nikhil Vojjala, Nikhila Sampath Kumar, Carolina Schinke

AME Clinical Trials Review

2026;

(25 February 2026)

PDF Full Text (1047) Peer Review File COI Form Open Access

Review Article

First-line treatment strategies and potential prognostic factors in patients with KRAS G12C-mutant non-small cell lung cancer

Malak Alharbi, Nour Nassour, Vaishali Deenadayalan, Grace K. Dy

AME Clinical Trials Review

2026;

(25 February 2026)

PDF Full Text (3249) Peer Review File COI Form Open Access

Editorial Commentary

Linvoseltamab, a new BCMA-targeting bispecific antibody for multiple myeloma: linking new with existing data

Michel Delforge

AME Clinical Trials Review

2025;

(25 December 2025)

PDF Full Text (1824) Peer Review File COI Form Open Access

Editorial Commentary

Challenging the status quo: ivonescimab’s bid to displace anti-PD-(L)1 inhibitors

Federico Monaca, Igor Gomez-Randulfe

AME Clinical Trials Review

2025;

(25 December 2025)

PDF Full Text (2071) Peer Review File COI Form Open Access

Editorial Commentary

PEARL trial: efficacy and challenges of durvalumab monotherapy in metastatic non-small cell lung cancer with PD-L1 expression of ≥25%

Tomohiro Onuki, Takehiro Uemura

AME Clinical Trials Review

2025;

(25 December 2025)

PDF Full Text (528) Peer Review File COI Form Open Access

Editorial Commentary

Recent developments in HER2-targeted therapy for patients with HER2-positive metastatic breast cancer: insights from the latest DESTINY-Breast12 trial results

Benedetta Campana, Beat Thürlimann

AME Clinical Trials Review

2025;

(25 December 2025)

PDF Full Text (1736) Peer Review File COI Form Open Access

Editorial Commentary

Beyond the surface: the hidden aggression of visceral pleural invasion in early-stage non-small cell lung cancer

Savvas Lampridis, Marco Scarci

AME Clinical Trials Review

2025;

(25 December 2025)

PDF Full Text (538) Peer Review File COI Form Open Access

Editorial Commentary

Insights into long-term safety and efficacy of evinacumab in homozygous familial hypercholesterolaemia

Irene Karungi, Kausik K. Ray, Amany Elshorbagy

AME Clinical Trials Review

2025;

(25 December 2025)

PDF Full Text (1245) Peer Review File COI Form Open Access

Editorial Commentary

Third- and later-line systemic therapy in metastatic gastric cancer: a persistent unmet need

Allan A. Lima Pereira, Jose M. Pimiento

AME Clinical Trials Review

2025;

(25 December 2025)

PDF Full Text (771) Peer Review File COI Form Open Access

Editorial Commentary

Six-year results of the CLL14 study—redefining long-term outcomes in chronic lymphocytic leukemia management

Andrea Visentin

AME Clinical Trials Review

2025;

(25 December 2025)

PDF Full Text (1518) Peer Review File COI Form Open Access

Editorial Commentary

Breaking through complexity: the expanding role of optical coherence tomography in PCI of complex coronary lesions

Francesco Bianchini, Francesco Burzotta

AME Clinical Trials Review

2025;

(25 December 2025)

PDF Full Text (756) Peer Review File COI Form Open Access

View more articles

Currently no content available!

Editorial Commentary

KEYNOTE-189 5-years update: setting a backbone for the next generation clinical research in advanced non-squamous non-small cell lung cancer without oncogenic addiction

Alessandra Merlini, Anis Cipi, Giorgia Ferrari, Paolo Bironzo

Published online: 11 June 2024

PDF Full Text (11251) Peer Review File COI Form Open Access

Editorial Commentary

Xaluritamig: a first step towards a new target, new mechanism for metastatic prostate cancer

Ruben Raychaudhuri, Michael T. Schweizer, Jessica E. Hawley, Lawrence Fong, Evan Y. Yu

Published online: 15 August 2024

PDF Full Text (9278) Peer Review File COI Form Open Access

Editorial Commentary

The Butterfly effect—will the MARIPOSA-2 study alter the trajectory of EGFR mutated non-small cell lung cancer (NSCLC)

Yuji Uehara, Aaron C. Tan

Published online: 06 June 2024

PDF Full Text (8269) Peer Review File COI Form Open Access

Editorial Commentary

Neoadjuvant FOLFIRINOX in resectable pancreatic cancer: impact of the NORPACT-1 trial

Eva Versteijne, Geertjan van Tienhoven, Anna M. E. Bruynzeel, Johanna W. Wilmink, Marc G. Besselink, Bas Groot Koerkamp; on behalf of the Dutch Pancreatic Cancer Group

Published online: 20 December 2024

PDF Full Text (7687) Peer Review File COI Form Open Access

Editorial Commentary

Yes to adjuvant osimertinib therapy in EGFR-mutated stage IB–IIIA non-small cell lung cancer post resection, but for how long? (ADAURA/NCT02511106)

Faustine Luo, Sai-Hong Ignatius Ou, Misako Nagasaka

Published online: 21 June 2024

PDF Full Text (7174) Peer Review File COI Form Open Access

Editorial Commentary

Intracranial efficacy of adagrasib in patients with KRAS G12C mutated non-small cell lung cancer (NSCLC): are results KRYSTAL clear?

Anuja Abhyankar, Grace K. Dy

Published online: 21 August 2024

PDF Full Text (6555) Peer Review File COI Form Open Access

Editorial Commentary

FLAURA in the real world: osimertinib in potentially trial-eligible and ineligible patients with EGFR-mutated advanced non-small cell lung cancer

Faustine X. Luo, Zhaohui Liao Arter, Sai-Hong Ignatius Ou, Misako Nagasaka

Published online: 04 December 2024

PDF Full Text (6422) Peer Review File COI Form Open Access

Editorial Commentary

Assessing the UNICANCER-PRODIGE 23 trial through the lens of nonoperative management

Wini Zambare, Aron Bercz, J. Joshua Smith

Published online: 13 May 2025

PDF Full Text (6007) Peer Review File COI Form Open Access

Editorial Commentary

The optimum balance between efficacy and toxicity with different doses of trastuzumab deruxtecan in HER2 mutated non-small cell lung cancer in DESTINY-Lung02 trial

Saurav Verma, Jacques Raphael

Published online: 02 September 2024

PDF Full Text (6006) Peer Review File COI Form Open Access

Editorial Commentary

Immunotherapy as the new standard of care for advanced endometrial cancer

Giovanna Vieira Giannecchini, Martina Parenza Arenhardt, Andreia Cristina de Melo

Published online: 03 April 2025

PDF Full Text (5938) Peer Review File COI Form Open Access

Editorial Commentary

Eradication of Helicobacter pylori and its impact on the incidence of gastric cancer

Luis Guilherme de Oliveira Silva, Fabian Fellipe Bueno Lemos, Fabrício Freire de Melo

Published online: 08 May 2025

PDF Full Text (5737) Peer Review File COI Form Open Access

Editorial Commentary

Induction therapy for acute myeloid leukemia: still nothing beyond 7+3?

Daniela Damiani, Mario Tiribelli

Published online: 20 June 2024

PDF Full Text (5546) Peer Review File COI Form Open Access

Editorial Commentary

Is zilebesiran a novel effective and uniquely administered agent for an expanding therapeutic armamentarium for blood pressure control?

John M. Flack

Published online: 24 February 2025

PDF Full Text (5398) Peer Review File COI Form Open Access

Editorial Commentary

Unpacking prostate-specific antigen dynamics and patient outcomes: insights from the ARASENS trial

Hayley Nicole Roberts, Corinne Maurice-Dror, Kim Nguyen Chi

Published online: 21 February 2025

PDF Full Text (5117) Peer Review File COI Form Open Access

Editorial Commentary

Targeting TIGIT in lung cancer: will it stick to the wall?

Jiaxin Niu, Saba Radhi

Published online: 21 June 2024

PDF Full Text (4596) Peer Review File COI Form Open Access

Editorial Commentary

What is the role of consolidation immunotherapy after chemoradiotherapy in stage III EGFR-mutant non-small cell lung cancer?

Toyoaki Hida

Published online: 20 October 2023

PDF Full Text (4461) Peer Review File COI Form Open Access

Editorial Commentary

A new ALK inhibitor is not a game changer, but an older one is!

Beatriz Jimenez Munarriz, Geoffrey Liu, Sam Khan

Published online: 12 October 2024

PDF Full Text (4332) Peer Review File COI Form Open Access

Editorial Commentary

Lisocabtagene maraleucel: transcending tolerability in CAR-T for mantle cell lymphoma

Danielle S. Wallace, Patrick M. Reagan

Published online: 23 October 2024

PDF Full Text (4126) Peer Review File COI Form Open Access

Editorial Commentary

Ripretinib as a second-line therapy for advanced gastrointestinal stromal tumors in the era of precision medicine

Toshirou Nishida, Osakuni Morimoto, Yoshihito Ide

Published online: 12 June 2024

PDF Full Text (3932) Peer Review File COI Form Open Access

Editorial Commentary

The immune “tsunami” has arrived at the shores of early-stage non-small cell lung cancer

Antonio Rossi, Ettore Mari, Domenico Galetta

Published online: 06 September 2023

PDF Full Text (3712) Peer Review File COI Form Open Access

Full Most Read article list >>

Journal Highlight more

AME Clinical Trials Review (AME Clin Trials Rev; ACTR) is an international, open-access, peer-reviewed online journal, publishing commentaries on all phases of clinical trials, including but not limited to the design, conduct, analysis, regulation and ethics. It is dedicated to sharing insights of the key opinion leaders to stimulate thought and discussion in clinical trials and facilitate the translation of the findings of clinical trials from bench to bedside, and to clinical practice. More >>